🟢 Neurosense Therapeutics Ltd is trading 6.6% up today after securing a patent for its ALS candidate PrimeC in Japan

Neurosense Therapeutics Ltd is trading at $0.81 (6.6%) up today, extending momentum from the prior session after the company announced it was granted a patent in Japan for its lead ALS drug candidate, PrimeC.

• The patent grant in Japan strengthens the company's intellectual property portfolio and supports the future commercial potential of PrimeC.
• The move follows a significant jump in the stock price during Tuesday's session, driven by investor optimism surrounding the regulatory milestone.